Skip to Main Content

Paper Details

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Leukemia
3
2023
Author NameAffiliation
Thomas Cluzeau
Thomas CluzeauCHU de Nice
Lionel Ad??s
Lionel Ad??s
Lionel Ad??sAssistance Publique-Hopitaux de Paris and Paris Cite University
  • 1 - 5

Datasets

Release 1.2